Caribou Biosciences Announces Dosing of First Patient in Phase 1 Clinical Trial Evaluating CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients with Relapsed or Refractory B Cell Non-Hodgkin LymphomaBusiness Wire • 07/12/21
Caribou Biosciences Eyes $100M NASDAQ Debut To Propel Off-The-Shelf CAR-T Therapies In Blood CancerBenzinga • 07/02/21